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Running Title: Human IL2RB deficiency 
 
Abbreviation List:  
 
ANA – Antinuclear antibodies  
ANCA – Antineutrophil Cytoplasmic Antibodies  
BFP – Blue Fluorescent Protein  
CADD – Combined Annotation Dependent Depletion  
FOXP3 – Forkhead Box P3  
GERP – Genomic Evolutionary Rate Profiling  
HSCT – Hematopoietic Stem Cell Transplant  
IL-2Rb – Interleukin-2 receptor b protein  
IL2RB – Interleukin-2 receptor b gene 
IPEX – Immunodysregulation Polyendocrinopathy Enteropathy X-linked  
MAF – Minor Allele Frequency  
MD – Molecular Dynamic  
NCF4 – Neutrophil Cytosolic Factor 4 
NKG2C – Killer Cell Lectin Like Receptor C2 also known as KLRC2  
PLZF – Promyelocytic leukemia zinc finger  
SIFT – Sorting Intolerant from Tolerant  
SYK – Spleen tyrosine kinase 
 
 
Short Summary (36 words):  
 
Zhang et al. identify human IL-2Rb deficiency as a cause of severe immune dysregulation. 
The hypomorphic gene mutations reveal variable IL-2Rb expression and function between 
different lymphocyte subsets as a means of selectively modulating immune responses.  
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Abstract (157 words)  
 
Interleukin-2, which conveys essential signals for immunity, operates through a 
heterotrimeric receptor. Here we identify human interleukin-2 receptor (IL-2R) b chain 
(IL2RB) gene defects as a cause of life-threatening immune dysregulation. We report three 
homozygous mutations in the IL2RB gene of eight individuals from four consanguineous 
families that cause disease by distinct mechanisms. Nearly all patients presented with 
autoantibodies, hypergammaglobulinemia, bowel inflammation, dermatological 
abnormalities, lymphadenopathy, and cytomegalovirus disease. Patient T lymphocytes 
lacked surface expression of IL-2Rb and were unable to respond to IL-2 stimulation. By 
contrast, natural killer cells retained partial IL-2Rb expression and function. IL-2Rb loss 
of function was recapitulated in a recombinant system, in which IL2RB mutations caused 
reduced surface expression and IL-2 binding. Stem cell transplant ameliorated clinical 
symptoms in one patient; forced expression of wild-type IL-2Rb also increased the IL-2 
responsiveness of patient T lymphocytes in vitro. Insights from these patients can inform 
the development of IL-2-based therapeutics for immunological diseases and cancer. 
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Introduction  
 
The interleukin-2 receptor (IL-2R) complex plays a central role in control of the immune 
response by integrating signals from the key cytokines IL-2 and IL-15. Three distinct receptors 
for IL-2 are generated by combinations of three IL-2R subunits: IL-2Ra (CD25), IL-2Rb 
(CD122) and IL-2Rg (CD132) – the latter, known as the common g chain, is also necessary for 
signaling by IL-4, 7, 9, 15 and 21. All three chains combine to form the high affinity IL-2R, 
which is constitutively expressed on CD4+ regulatory T cells (Tregs), and induced upon activation 
of CD4 and CD8 T cells, B cells and some myeloid-derived subsets (Liao et al. 2013; Busse et 
al. 2010). A second receptor, which binds IL-15 and IL-2 with intermediate affinity, is comprised 
of only the IL-2Rb and IL-2Rg subunits; it is constitutively expressed on resting CD8+ T cells 
and natural killer (NK) cells. The a subunit alone is a low affinity receptor. Upon ligand binding, 
the IL-2Rb and IL-2Rg subunits undergo tyrosine phosphorylation which, in turn, induces the 
phosphorylation of the associated Janus tyrosine kinases (JAK) 1 and 3, that phosphorylate the 
signal transducer and activator of transcription 5 (STAT5) transcription factor (Waldmann et al. 
2006). STAT5, once dimerized and translocated to the nucleus, induces a pro-survival and 
proliferative transcription program. Interleukin-2 (IL-2) is primarily produced by CD4+ T helper 
cells following T cell receptor (TCR) engagement with costimulation (Boyman et al. 2012). It 
potently stimulates T cell proliferation, differentiation (promoting Th1, Th2, and Th9, and 
suppressing Th17 polarization) and cytolytic effector activity. It also plays a key role in 
peripheral tolerance by promoting the generation and maintenance of regulatory T cells (Treg) 
and antigen-specific peripheral T cell clonal deletion (Hatakeyama et al. 1989; Takeshita et al 
1992; Lenardo, 1991). CD25 deficient mice demonstrate grossly normal early B and T cell 
development, but lymphadenopathy and impaired T cell activation and clonal deletion. As they 
age, these mice develop autoimmune and inflammatory disease (e.g. hemolytic anemia and 
inflammatory enteropathy) (Willerford et al. 1995). Humans with CD25 deficiency have a 
similar phenotype, developing prominent autoimmune disease with less consistent evidence of 
immunodeficiency, and resembling patients with IPEX, due to FOXP3 deficiency, thus 
indicating the impact of loss of the high-affinity IL-2 receptor can be ascribed to a loss of 
peripheral tolerance (Scharfe et al. 1997, Caudy et al. 2007). 
  
The role in immunity of IL-2Rb is less well understood, and no monogenic cause of 
human IL-2Rb deficiency has yet been described. Although a case of NK-SCID was previously 
reported, in which the patient did not express IL-2Rb, no mutation within IL2RB was identified 
(Gilmour et al. 2001). IL-2Rb-deficient mice had severe autoimmunity and diminished cytolytic 
effector function, with splenomegaly, lymphadenopathy, elevated IgG1 and IgE levels, and ANA 
and anti-dsDNA autoantibodies (Suzuki et al. 1995). They succumbed to autoimmunity around 
12 weeks unless rescued by the adoptive transfer of Tregs (Malek et al. 2002). Despite showing 
evidence of activation, e.g. increased CD69, the T cells of IL-2Rb-deficient mice failed to 
respond to stimuli including IL-2, PMA, and ionomycin, and had diminished CD8+ T cell 
cytolytic activity when re-challenged (Suzuki et al. 1995). This, plus the observation that they 
have reduced NK cell numbers (Suzuki et al. 1997), implies that IL-2Rb  deficiency in mice 
could produce susceptibility to infection in addition to T cell activation and autoimmunity. IL-
2Rb-mediated signaling is implicated in pathways known to be important in human autoimmune 
disease, and loci containing it have been associated with asthma and juvenile-onset arthritis in 
genome-wide association studies (Moffatt et al. 2010, Hinks et al. 2013).  Moreover, high-dose 
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IL-2 therapy is approved for use in renal cell carcinoma and malignant melanoma and 
encouraging early phase studies of low-dose IL-2 in Type-1 diabetes, graft-versus-host disease 
and systemic lupus erythematosus have led to over 14 on-going phase 2 and 3 trials 
(Ahmadzadeh et al. 2006; Ye et al. 2018). It will thus be important to understand the biology of 
IL-2Rb, and the impact of IL-2Rb deficiency, in humans. To this end, we describe human 
homozygous recessive IL-2Rb deficiency in four consanguineous families with 8 affected 
individuals, which was associated with autoimmunity and immunodeficiency. 
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Results  
 
Clinical phenotype and genotype of patients in a combined immunodeficiency/autoimmunity 
cohort. 
 
We investigated the medical records and clinical data of eight affected individuals from 
four consanguineous families with South Asian, Middle Eastern, and Eastern European origins, 
residing in countries on three different continents. All the patients have a history of severe 
immunodeficiency and autoimmunity (Figure 1 and Supplementary Table 1). Kindred A includes 
a six-year-old boy (A1) and his three-year-old sister (A2) born to first cousin Pakistani parents 
(Figure 1A). A1 was initially hospitalized at the age of two for thyrotoxicosis secondary to 
Graves’ disease and A2 was hospitalized at the age of six months for failure to thrive and 
persistent diarrhea (Supplementary Table 1). Since their initial hospital course, A1 has developed 
severe gastroenteritis and dermatitis and A2 has had pulmonary, gastrointestinal, and urinary 
infections as well as ANCA+ vasculitis. Patient A1 has improved with rituximab treatment but 
continues to be intermittently ill. Patient A2 received an allogeneic hematopoietic stem cell 
transplant (HSCT) and has recovered with no sequelae. Kindred B consists of a girl (B1) born to 
related parents of South Asian origin. B1 initially presented in a collapsed state with severe 
diarrhea at the age of 4 weeks and was found to have enteropathy, dermatitis, and later CMV 
viremia with hepatitis. She improved with immunosuppression and antiviral therapy but 
ultimately succumbed to probable CMV pneumonitis and respiratory failure after HSCT. 
Kindred C includes a boy (C1) and his first female cousin (C2) born to consanguineous Saudi 
Arabian parents. C1 presented with suppurative ear infections at the age of 6 months. C2 
presented with chest and ear infections and diarrhea at the age of 2 months. Subsequently, both 
suffered recurrent otitis, severe dermatitis, CMV viremia and food allergies. C1 and C2 died 
from probable CMV pneumonitis at the age of 3 years old and 18 months old, respectively.  
 
Kindred D consists of two fetuses (D1, D3) and a premature female neonate (D2) 
conceived by a Romany family living in France. D1, D2, and D3 were found to have intra-
uterine growth retardation and reduced fetal movement; skin-like floating membranes were also 
present in the amniotic fluid in all three cases. While it was not possible to evaluate the fetuses 
for immunodeficiency, autoimmune skin desquamation in utero is consistent with echogenic 
debris findings in prenatal IPEX patients (Louie et al. 2017). D2 was delivered pre-maturely by 
emergency Cesarean section at 31 weeks’ gestation, but she died two hours later of respiratory 
failure. D1 and D3 pregnancies were terminated due to fetal abnormalities at 25 weeks and 30 
weeks, respectively. In summary, all the patients who had survived the neonatal period had 
recurrent infections, as well as autoimmune disease, leading to early death in most cases.  
 
Immune dysregulation was a key shared feature across these four kindreds, manifest as 
enteropathy, dermatitis, autoimmune hemolytic anemia, and hypergammaglobulinemia (Figure 
1). All the children with IL-2Rb deficiency also had recurrent infections, including defective 
handling of herpesviruses (CMV or EBV viremia in all; CMV disease in 4 of 5; Supplementary 
Table 1). Chest radiographs of patient A2 revealed a pleural effusion and numerous small 
pulmonary nodules and tree-in-bud opacities suggestive of CMV pneumonia in the context of 
CMV viremia (Figure 1B). CT imaging also revealed hepatosplenomegaly and marked 
lymphadenopathy in A2 (Figure 1B); a clinical feature that was noted in all five patients.  
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Skin abnormalities are a key hallmark of this disease. A1, A2, B1, C1, and C2 all had 
severe dermatitis and D1, D2, and D3 had patches of hyperkeratosis and significant infiltration of 
B and T lymphocytes on skin immunohistochemistry (Figure 1C). Four out of the five children 
have also had severe diarrhea and infectious/autoimmune enteropathy.  Endoscopy of patient B1 
showed villous atrophy and gastrointestinal biopsies revealed chronic inflammatory infiltration 
of the duodenum and rectum (Figure 1D). Additional hallmarks of disease include: autoimmune 
hemolytic anemia (4/5 patients) and hypergammaglobulinemia (5/5 patients) comprising 
predominantly class-switched isotypes: IgA, IgG, and IgE (Figure 1E and Supplementary Table 
2). Overall, CD4 cell numbers were normal but two of the patients had low CD8 T cell counts, 
while NK numbers were increased (Supplementary Table 2). T cell proliferative responses 
measured in B1 were also globally impaired (Supplementary Figure S1).  
 
Identification of protein-coding mutations in the gene encoding IL-2Rb (CD122)  
 
Because of the early onset of disease in consanguineous families, we sought a genetic 
cause by whole exome DNA sequence analysis of the 4 kindreds.  We identified three different 
IL2RB gene mutations (Figure 2A). For Kindreds A and B, the IL2RB chr22: g.37538526 A>G 
(p.Leu77Pro) missense variant was prioritized. The mutation occurs in exon 4 (out of 10) and is 
not found in dbSNP, ESP, or ExAC databases, but has a minor allele frequency (MAF) of 
0.00001218 in gnomAD. The p.Leu77Pro mutation introduces a restrictive proline-proline motif 
in the extracellular D1 domain of IL-2Rb (Figure 2B). For Kindred C, the g.37539634 C>T 
(p.Ser40Leu) missense variant was prioritized and not found in any databases of genomic 
variation. The mutation appears to be located at the interface of IL-2Rb and IL-2 (Figure 2B). 
For Kindred D, a g.37537259 G>A (p.Gln96*) stop-gain mutation was identified and also not 
found in any databases. This mutation would lead to significant truncation of the 552 amino acid 
protein. Due to the predicted deleterious nature of these variants, their segregation with disease 
and the similarity in phenotype with a mouse knock-out model, IL2RB represented an attractive 
candidate disease gene. Other prioritization criteria that were taken into consideration include: 
Combined Annotation Dependent Depletion (CADD) score, quality of reads, Genomic 
Evolutionary Rate Profiling (GERP) conservation score, co-segregation of alleles, sorting 
intolerant from tolerant (SIFT) score, polymorphism phenotyping (PolyPhen2) score, tissue 
specific expression levels, structural modeling, and primary literature reviews leading to the 
conclusion that these variants were likely responsible for the disease. Other rare variants that 
were candidate disease alleles in individual families are listed in Supplementary Table 3; the 
deleterious IL-2RB alleles were the only variants that correlated with disease in all families. 
 
 
The L77P IL-2Rb missense mutation causes loss of surface expression and function in T cells  
 
At baseline, IL-2Rb is normally highly expressed on the surface of NK cells and to a 
lesser extent on T cells; however, patients with the L77P mutation have markedly decreased 
surface expression of IL-2Rb on NKs, CD4 T cells, and CD8 T cells as assessed by flow 
cytometry (Figure 2C-D). A healthy heterozygous parent showed intermediate surface 
expression of IL-2Rb (Figure 2D). Despite diminished cell surface IL-2Rb expression, 
immunoblotting of cytosolic lysates of patient NKs, CD4 T, and CD8 T cells revealed strikingly 
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more IL-2Rb than healthy controls (Figure 2E-G). This implied that the mutant L77P IL-2Rb 
protein was sequestered intracellularly due to misfolding and an inability to properly traffic to 
the cell surface for subsequent turnover. In keeping with this hypothesis, the faster migration of 
L77P IL-2Rb protein relative to WT IL-2Rb is likely due to incomplete glycosylation branching 
modifications that are added post-translationally outside the endoplasmic reticulum (ER) (Figure 
2E). In addition, the affected neonate (D1) and fetuses (D2, D3) from Kindred D with the more 
severe p.Q96* stop gain mutation, resulting in a significant truncation, had no IL-2Rb protein 
expression (Figure 2H).  
 
Reduced signaling by mutant IL-2Rb  proteins encoded by patient alleles 
 
 We reconstituted the IL-2R complex in HEK293T cells via transfection of expression 
plasmids encoding IL-2Rb, and IL-2Rg, JAK-3, and STAT5; this system can transduce a signal 
from IL-2 to intracellular mediators such as the STAT signaling proteins (John et al. 1999; Majri 
et al. 2017). We used this system to compare the protein-coding sequences of the wild-type or 
L77P mutant IL-2Rb and GFP (separated by a P2A sequence) under the control of a tetracycline 
(Tet) -inducible promoter. As expected, cells transfected with the wild-type plasmid showed 
increasing IL-2Rb surface expression that correlated with increasing GFP expression after Tet 
induction (Figure 3A). However, cells transfected with the mutIL2RB plasmid showed very low 
surface IL-2Rb expression, except at very high levels as judged by GFP co-expression (Figure 
3A). Given similar levels of expression of the BFP control for tetracycline-inducible system and 
GFP expression, wild-type IL-2Rb is expressed at much greater abundance on the cell surface 
than the L77P mutant (Figure 3B). As observed in the L77P mutant patient lymphocytes, there is 
an increase in total cytoplasmic IL-2Rb protein, despite decreased surface expression, in cells 
transfected with the mutant (Figure 3C). Confocal imaging of the live HEK293T cells transfected 
with an ER marker (KDEL-BFP) and wtIL-2RB-GFP or mutIL-2RB-GFP showed that mutIL-
2RB-GFP co-localized with KDEL-BFP and therefore was being sequestered in the ER (Figure 
3D), as we hypothesized from the patient data. Together these experiments demonstrate that even 
when the L77P IL-2Rb is reconstituted in an exogenous HEK293T cell line, the allele encodes a 
mutant protein that is sequestered in the ER and inefficiently reaches the cell surface, thus 
recapitulating the patients’ cellular phenotype.  
 
 Using our reconstituted receptor system, we also compared the Q96* and S40L alleles to 
the L77P allele for IL-2Rb surface expression and phosphorylation of STAT5 (pSTAT5) after 
IL-2 stimulation (Figure 3E-F). As expected, the Q96* allele, which encodes an early stop codon 
and truncation of IL-2Rb prior to the transmembrane domain, generated no IL-2Rb surface 
expression and showed no pSTAT5 response to IL-2 stimulation (Figure 3E-F). The low level of 
L77P expressed at the cell surface was nonetheless capable of supporting some phosphorylation 
of STAT5 in response to IL-2, indicating hypomorphic behavior of this allele. By contrast, the 
S40L IL2RB allele promoted IL-2Rb surface expression but conferred no response to IL-2 
stimulation (Figure 3E-F). Molecular modelling of the S40L mutant showed that the substitution 
introduces steric clashes with main chain atoms in the BC2 loop (residues 157-165) in the D2 
domain, which we predict would disrupt the IL-2 binding interface of IL-2Rb (Figure 3G), 
consistent with this variant’s lack of responsiveness to IL-2 (Figure 3F). In addition, we 
performed molecular dynamics (MD) simulations on WT IL-2Rb and the L77P and S40L 
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mutants. After 100 ns of simulation, residues 76-78 in the L77P mutant adopt a different 
backbone conformation and do not contribute a b-strand to one of the b-sheets in the D1 domain 
as in WT (Supplementary Figure S2), which is consistent with our functional evidence that the 
L77P mutant is misfolded and sequestered in the ER. In an MD simulation of the S40L mutant, 
the BC2 loop and specifically key IL-2 binding residues His159 and Tyr160 adopted a 
conformation that would clash with an IL-2 molecule bound in the same position as in the wild 
type complex. The D1 domains also rotated relative to the D2 domain in the S40L mutant by 
approximately 15˚, altering the shape of the IL-2 binding surface (Figure 3G). As predicted by 
the MD simulation, the S40L mutant had significantly decreased affinity to IL-2 - comparable to 
levels in the negative control without IL-2Rb based on a biotinylated cytokine-streptavidin 
fluorophore flow cytometry assay (Figure 3H). Thus, by using this reconstituted system, we 
define three distinct mechanisms in humans for IL-2Rb deficiency by showing that it can occur 
due to an absence of IL-2Rb (Q96*), impaired surface expression (L77P), and decreased binding 
of IL-2 (S40L).  
 
Patient T cells show impaired IL-2Rb-dependent signaling 
 
We next explored the impact of IL2RB mutations on interleukin signaling in patient T 
lymphocytes by measuring STAT3 and STAT5 phosphorylation after interleukin stimulation 
(Figure 4). High dose IL-2 normally triggers tyrosine phosphorylation of the cytoplasmic tails of 
the IL-2Rb and IL-2Rg and downstream STAT1, STAT3, and STAT5 phosphorylation via the 
JAK1 and JAK3 Janus kinases. Consistent with a loss of function phenotype, we found that 
CD4+ and CD8+ T cells, which were available for laboratory analysis from patients A1 and B1, 
failed to phosphorylate STAT5 in response to IL-2 or IL-15 stimulation whereas robust 
phosphorylation was observed in cells from healthy controls (Figure 4A-E). By contrast, patient 
T cells were fully responsive to IL-7 stimulation, indicating that the defect of IL-2Rb-dependent 
signaling was selective (Figure 4E). Interestingly, CD4+ T cells from A0, the father with a 
heterozygous L77P genotype, have enough surface expression of IL2-Rb to phosphorylate 
STAT3 and STAT5 at a comparable level to healthy controls (Figures 4A and B) although there 
was a trend towards reduced STAT3 and STAT5 phosphorylation in heterozygous CD8+ T cells 
(Figures 4C and D). Thus, surface IL-2Rb deficiency impairs downstream STAT 
phosphorylation in response to IL-2 and IL-15 stimulation in a cell-type- and receptor 
expression-dependent manner.  
 
In keeping with current understanding of the critical role of IL-2 signaling in the 
maintenance of regulatory T (Treg) cells in the periphery, the CD25hiFoxP3+ CD4+ T cell 
compartment was almost empty (Figure 4F). Consistent with the inability of peripheral T cells to 
utilize and consume IL-2 and IL-15, the patients had elevated levels of serum IL-2 and IL-15  
and their T cells did not upregulate CD25 expression when stimulated with the same cytokines 
(Figure 4G and 4H). Taken together, the profound reduction of STAT5 signalling within the 
CD4+ T cell compartment, inability to upregulate CD25, and the absence of CD25hiFOXP3+ Tregs 
closely mirrors the situation in IL2RB-knock out mice and other known disorders of Tregs such 
as monogenic deficiencies of FOXP3 and CD25. Therefore, this could explain at least in part the 
various autoimmune manifestations we observed early in life.    
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Hypomorphic nature of L77P IL2RB mutation in NK cells  
 
The NK compartment of IL2RB-knockout mice is almost completely depleted, but our 
patients bearing hypomorphic mutations instead showed an expansion of NK cells 
(Supplementary Table 2) and an increase in CD56bright relative to CD56dim NKs (Figure 5A) 
(Suzuki et al. 1995). These unusually abundant CD56bright NK cells expressed abnormally high 
levels of the cytotoxic effector proteins perforin and granzyme B (Figure 5B). A similar increase 
of the human CD56bright NK cell compartment has been observed in patients experiencing 
chronic cytokine exposure through low dose IL-2 therapy (Ito et al, 2014), CD25 blockade 
(Bielekova et al, 2006) or low dose IL-15 treatment (Dubois 2017), associated with increased ex 
vivo cytotoxic function. Indeed, residual expression of IL-2RbL77P was clearly detectable (Figure 
2C and 2D), just as it had been on the surface of transfected 293T cells. Moreover, this residual 
IL-2Rb expression could sustain IL-2 and IL-15 signal transduction and downstream STAT5 
phosphorylation (Figure 5C).  
 
We were able to examine NK cell effector function systematically in patient B1.  When 
provided with the target cell line K562, patient NK cells degranulated to a similar extent to 
control NK cells, with evidence of priming by both IL-2 and IL-15 (Figure 5D and S3B). 
Moreover, cytotoxicity towards K562 was increased in patient NK cells compared to control 
with IL-2 or IL-15 priming (Figure 5E).  However, patient NK cells were poor producers of 
IFN  in response to the same cytokines (Figure 5F and S3C). This effect was IL2Rb-dependent, 
because the same cells could produce normal levels of IFNg when stimulated with IL-12. These 
data support the conclusion that L77P is a hypomorphic mutation of IL-2Rb  that all but 
abolishes IL-2 signaling in T cells but still transduces residual signaling in high IL-2R-
expressing cell subsets like NK cells. As a result, NK cells persist and can respond to the IL-2 
and IL-15 that we speculate are normally produced but not consumed by IL-2Rb-deficient T 
cells. Our data show that various outcomes of IL-2Rb signaling are differentially affected by the 
L77P variant – from absent (IFNg production, Figure 5F and S3C) to reduced (CD25 
upregulation, Figure 4H and S3A) to supra-normal (cytotoxicity, Figure 5E); however, these 
findings are based only on a single patient and firm conclusions are difficult due to donor 
variability. 
 
With this evidence of altered NK phenotype in mind, we hypothesized that NK 
differentiation might be perturbed in other ways.  In particular, the NK compartment is known to 
adapt to the presence of CMV by expansion of memory-like cells that co-express NKG2C and 
CD57 on their surface (Lopez-Verges et al, 2010).  Such cells were strikingly absent from both 
A1 and B1 (Figure 5G and 5H), even though an NKG2C+ population was present, suggesting 
CMV recognition.  To explore whether there was a general problem with NK maturation, we 
examined the expression of the transcription factor PLZF and its downstream targets SYK and 
FcεRIg (Lee et al., 2015 and Schlums et al., 2015).  This analysis confirmed a failure of patient 
NKG2C+ NK cells to complete their differentiation by downregulating PLZF, SYK, and FcεRIg, 
as well as upregulating CD57 (Figure 5I and 5J). We conclude that the NK compartment and its 
response to CMV is systematically altered in the context of the hypomorphic IL2RB mutation.  
We suggest that this is at least in part responsible for the observed clinical susceptibility to CMV 
disease.   
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Lentiviral rescue of IL2RB and STAT phosphorylation in patient T cells 
 
 Finally, we performed complementation by lentiviral transduction of patient T cells with 
wild-type IL-2Rb (Figure 6). Patient T cells were activated with anti-CD3 and anti-CD28 beads, 
transduced with lentiviral WT-IL2RB and GFP, and cultured in the presence of IL-7 rather than 
IL-2. Patient CD3+ T cells were transduced with greater than 50% transfection efficiency (Figure 
6A) and expressed high levels of IL-2Rb on the cell surface (Figure 6B). While patient T cells 
that were not transduced with WT-IL2RB failed to respond to high dose IL-2 stimulation as 
expected, transduced patient T cells, when stimulated with IL-2, were able to phosphorylate 
STAT3 and STAT5 (Figure 6C and 6D). Transduction of WT-IL2RB did not restore IL-2 
response back to control levels (Figure 6E), but this may be due to heterodimerization of L77P 
IL-2Rb and WT IL-2Rb leading to partial ER sequestration of the WT chain (Pillet et al., 2008). 
Nonetheless, lentiviral transduction of WT-IL2RB partially rescues STAT phosphorylation in 
response to IL-2 in patient T cells indicating that the failure of IL-2 response in this patient is due 
to the genetic abnormality of IL2RB  
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Discussion  
 
Here we provide the first report of autosomal recessive IL-2Rb deficiency in four 
pedigrees harboring five affected liveborn children with immunodeficiency and autoimmune 
disease and three perinatally affected fatalities. Clinical hallmarks of the disease include 
prominent immune dysregulatory phenomena such as enteropathy, skin abnormalities, 
autoimmune hemolytic anemia, and hypergammaglobulinemia, together with susceptibility to 
respiratory and herpesvirus infections. We demonstrate that the three mutant alleles cause IL-
2Rb deficiency by different biochemical mechanisms. Kindreds A and B have the hypomorphic 
L77P IL-2Rb mutation which interferes with egress from the endoplasmic reticulum. We 
discovered that this abrogates surface expression and IL-2 signaling in T cells, but that NKs not 
only retain modest surface expression and responsiveness to IL-2 but quite potent cytolytic 
activity. Kindred C possesses the S40L IL-2Rb mutant, which has decreased responsiveness to 
IL-2 despite being expressed on the cell surface. Our analysis shows that this is due to an amino 
acid side group clash in the receptor: ligand interaction site. This mutation may also be 
hypomorphic in nature given IL-2Rb expression, but studies to characterize this were limited by 
sample availability. Kindred D has the most severe Q96* IL-2Rb stop gain mutation. The 
severity of this mutation is reflected not only in the perinatal phenotype in the neonate and 
fetuses but also by the complete absence of IL-2Rb expression and IL-2 signaling. However it 
cannot be excluded that the severe phenotype in Kindred D may be due to  the added effects of 
other genetic variants. A NCF4 variant also co-segregated in the kindred but the specific variant 
is reported in ClinVar to be likely benign and is not very rare, with a MAF > 0.001. Despite the 
differences in mechanism, all the mutations cause IL-2Rb dysfunction in some manner and lead 
to a similar constellation of clinical features.  
 
Specifically, the hypomorphic L77P IL-2Rb mutation highlights the significance of 
variable IL-2Rb expression in different lymphocyte subsets as a means of modulating immune 
function. The L77P mutation causes ER sequestration and thus minimal IL-2Rb surface 
expression in patient lymphocytes despite increased total IL-2Rb protein. This decreased IL-2Rb 
surface expression prevents downstream STAT3 and STAT5 phosphorylation following IL-2 
stimulation in T cells. By contrast, NK cells are still capable of responding to IL-2 and maintain 
normal cytotoxic function, likely due to the cell’s intrinsic high expression of IL-2R. 
Nonetheless, abnormalities of NK adaptation to CMV and IFNg production may contribute to the 
viral susceptibility observed in most patients. 
 
 While the human IL-2RB deficiency shares many similarities with the IL2RB knockout 
(KO) mouse and FOXP3-deficient IPEX patients, there are interesting key differences. Like the 
knockout mouse (Suzuki et al. 1995), the IL-2RB deficient patients have autoimmune hemolytic 
anemia, elevated autoantibodies, and hypergammaglobulinemia (IgG and IgE), 
lymphadenopathy, and splenomegaly. In vitro both the IL-2RB KO mouse and IL-2RB deficient 
human T cells proliferate poorly in response to IL-2 and TCR stimulation. Human IL-2RB 
disease reveals that deficient IL-2RB also leads to skin abnormalities and enteropathy, which is 
not seen in the KO mouse. In addition, in the human patients, we observed an expansion of NK 
cells and skewing of the NK compartment, while a reduction of NK cells was recorded in the KO 
mouse (Suzuki et al. 1997). These observations might reflect the hypomorphic nature of the 
human disease alleles compared with complete loss of function in the mouse model and/or 
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differences in the role of IL-2/15Rb in NK maturation in the two species (Renoux et al. 2015). 
Mirroring the KO mouse, the IL-2Rb deficient patients also lack CD25+ FoxP3+ regulatory T 
cells, thus explaining the overlap in clinical features of immune dysregulation with IPEX 
syndrome. Enteropathy, dermatitis, and hemolytic anemia were seen in both disorders, although 
only one IL-2RB patient (A1) presented with any endocrinopathy – a hallmark of IPEX.  A 
distinctive component of IL-2RB deficiency is the presence of beta-herpesviral disease in 
addition to severe autoimmune/inflammatory disease.  This combination recalls CD25 
deficiency, where beta-herpesviral susceptibility has also been noted (Scharfe et al. 1997, Caudy 
et al. 2007). The presence of both immunodeficiency and autoimmune/inflammatory disease as 
defining features of IL-2RB and CD25 deficiency states is consistent with the multi-faceted role 
of IL-2 signaling biology in the immune system. 
 
 The current definitive treatment for IL-2Rb deficiency is hematopoietic stem cell 
transplant. Patient A2 received an allogeneic HSCT and has had complete resolution of her 
symptoms. However, there are high risks associated with HSCT, as exemplified by patient B1, 
and the hope is that understanding the pathophysiological mechanism of IL-2Rb deficiency can 
guide the development of novel therapeutics. One approach might be to re-purpose IL-2 anti-IL-
2 antibody complexes (Boyman et al. 2006), IL-2 superkine (Levin et al. 2012), ortho-IL2 
analogs (Sockolosky et al. 2018), or IL-2 Fc fusion proteins (Vazquez-Lombardi et al. 2017) as a 
potential means of hyper-stimulating residual surface IL-2Rb. Monoclonal anti-human IL-2 
antibody MAB602 (mouse S4B6) in complex with IL-2 was found to selectively promote 
proliferation of effector T cells, while the antibody clone 5344 (mouse JES61) induced 
proliferation of Tregs (Boyman et al. 2006). Similarly, the H9 IL-2 superkine was engineered to 
have enhanced binding to IL-2Rb independent of CD25 (Levin et al. 2012). Another approach to 
hyper-stimulating the IL-2Rb mutant would be to develop an orthoIL-2 with specific binding to 
the mutant (Sockolosky et al. 2018). The fact that we find hypomorphic mutations in the liveborn 
children suggests that an approach involving hyper-stimulating the IL-2 axis may ameliorate 
disease. 
 
In summary, our identification of human IL-2Rb deficiency as a monogenic cause of 
immunodeficiency and autoimmunity provides insight into one of the principal signaling 
pathways of the immune activation and peripheral tolerance and should prompt prenatal 
screening of IL-2RB mutations and genetic counseling in families at risk. 
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Methods  
 
Human Subjects 
Written informed consent was provided by all human subjects or their legal guardians in 
accordance with the 1975 Helsinki principles for enrollment in research protocols that were 
approved by the Institutional Review Board of the National Institute of Allergy and Infectious 
Diseases, National Institutes of Health and the Newcastle and North Tyneside Research Ethics 
Committee 1, UK. Patient and healthy control blood was obtained at Starship Children’s 
Hospital in Auckland, New Zealand, Addenbrooke’s Hospital in Cambridge, United Kingdom, 
and Great North Children’s Hospital in Newcastle, United Kingdom under approved protocols.  
 
Genetic Analysis  
DNA was obtained from probands and family members by isolation and purification from 
peripheral blood mononuclear cells (PBMCs) using Qiagen's DNeasy Blood and Tissue Kit. The 
DNA was then submitted for whole exome sequencing (WES) by Illumina sequencers in the 
United States, United Kingdom, France, and Saudi Arabia. The reads were filtered for sequence 
quality and then mapped on to the h19 human genome reference by Burrows-Wheeler Aligner 
with default parameters. Alignment, variant calling, and annotation were performed by the in-
house bioinformatics core using the Genome Analysis Toolkit version 3.4 (Broad Institute) and 
GEMINI (GEnome MINIng). The IL2RB variant was confirmed by Sanger sequencing of PCR 
amplification products of cDNA, generated by reverse transcription of RNA using SuperScript 
IV VILO kit (Thermo) and the following PCR primers:  F-CCTGTGTCTGGAGCCAAGAT and 
R-GGGTGACGATGTCAACTGTG (Sigma Aldrich) or F-CCTCACAGTGGTTGGCACA and 
R-GCACTCTCTCCCTGGGTG (Sigma Aldrich).  
 
Cells and Media 
Primary patient or control PBMCs were obtained from whole blood subjected to 
Histopaque/Ficoll density gradient separation. The PBMCs were then washed with PBS and 
frozen in complete RPMI with 10% DMSO in liquid nitrogen for later use or -80°C for transport. 
HEK293T and K562 cells were obtained from the European Collection of Authenticated Cell 
Cultures and tested mycoplasma-free (ECACC). Human cells were cultured in RPMI (Sigma 
Aldrich) or DMEM (Sigma Aldrich) supplemented with 10% heat-inactivated fetal bovine serum 
(Sigma Aldrich), 1% penicillin/streptomycin (Gibco), and 1% Glutamax (Gibco). Recombinant 
human IL-2, IL-7, and IL-15 (Peprotech) was used for stimulation. XVIVO 15 media (Lonza) 
supplemented with 1-10% human AB serum (Sigma Aldrich) was used for STAT 
phosphorylation assays. 
 
Antibodies 
The following monoclonal primary rabbit anti-human antibodies from Cell Signaling 
Technologies (CST) were used for Western blot analysis: anti-IL2RB, anti-GFP, anti-vinculin, 
and anti-IL2RA. Rabbit anti-beta actin (Abcam) and goat anti-IL2RG (Thermo Fisher Scientific) 
were also used. Secondary HRP-linked anti-rabbit IgG and anti-goat IgG antibodies (CST) were 
used to conjugate to the respective primary antibodies. The following flow cytometry antibodies 
are from Biolegend: CD3-AF700, CD3-PerCp-Cy5.5, CD3-BV705, CD4-Pacific Blue, CD56-
PE-Cy7, CD122-PE-Dazzle, CD132-APC, CD25-APC-Cy7, CXCR5-FITC, CD45RA-PerCp-
Cy5.5, CD127-APC, HLA-DR-Pacific Blue, and Live/Dead-Zombie Aqua, pSTAT3-AF647, 
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CD20 (2H7), PD-1 (EH12.2H7), CD45RA (HI100), CD127 (A019D5), TNFα (MAB11), CD56 
(5.1H11), CD56 (HCD56), CD16 (3G8), CD19 (HIB19), CD122 (TU27), CD57 (QA17A04), 
Syk (4D10.2) and Perforin (dG9); Thermo Fisher Scientific: CD4-APC-eF780, CD56-APC-
eF780, TCRγδ (B1.1), and TCRVα24Jα18 (6B11); BD Bioscience: CD25-PE, pSTAT5-AF488, 
CD4 (SK3), CD3 (UCHT1), CD8 (RPA-T8), CD25 (2A3 or M-A251), CCR7 (3D12), CD45RO 
(UCHL1), Granzyme B (GB11), IFN-γ (B27), STAT5 (47/Stat5), S6 (N7-548), FoxP3 
(259D/C7), CD127 (HIL-7R-M21), CD56 (NCAM16.2), CD28 (CD28.2), CD95 (DX2), CD16 
(3G8), CD107a (H4A3), CD69 (FN50), IL-2 (5344.111) and PLZF (R17-809); Miltenyi: CD132 
(REA313); Merck: FcεRIγ (polyclonal) and R&D Systems: NKG2C (134591). Cell trace violet 
(Thermo Fisher Scientific, MA, USA) was used to label K562 cells. Cell viability was assessed 
using Zombie aqua or NIR, 7-AAD (all from Biolegend, CA, USA) or LIVE/DEAD Fixable 
Green (Invitrogen, Thermo Fisher Scientific, MA, USA). 
 
Flow Cytometry  
Cells were pelleted by centrifugation and stained with antibodies in FACS Buffer (1-2% FBS, 
0.05% sodium azide, and 2-5 mM EDTA in PBS) at 4°C for 30-60 minutes. The stained cells 
were then washed with PBS or FACS buffer, pelleted, and resuspended at ~1x106 cells/ml in 
FACS Fix Buffer (FACS Buffer with or without 1% PFA) for flow cytometry analysis (Fortessa, 
Symphony A5, or FACS Aria Fusion systems). The flow data was analyzed using FlowJo or 
Treestar.  
 
Western Blot 
Cells were lysed with NuPage LDS sample buffer (Thermo Fisher Scientific) at the 
concentration of 105 cells per 15uL LDS supplemented with 10% BME and Benzonase Nuclease 
(Sigma Aldrich). The samples were then denatured at 70°C. Protein lysates were separated by 
SDS-PAGE on 4-12% Bis-Tris precase gels (Invitrogen) and transferred to a PVDF membrane 
(Invitrogen) by iBlot (Thermo Fisher Scientific) or wet transfer. Membranes were then blocked 
in milk with 5% Tris-buffered saline with 0.01% Tween-20) TBST for an hour at room 
temperature and then incubated with primary antibody in milk or 5% BSA overnight at 4°C. The 
membrane was washed for 3 x 10 minutes with TBST at room temperature and then stained with 
HRP-linked secondary antibody in milk for 1 hour at room temperature. After 3 x 10 minute 
washes with TBST and 1 x 10 minute wash with PBS, the membrane was exposed to enhanced 
chemiluminescent (ECL) substrates (Thermo Fisher Scientific) and developed by film.   
 
Flow Cytometry Based STAT Phosphorylation Assay 
At the NIH, PBMCs were thawed in XVIVO media (Lonza) with 10% human AB serum 
(Sigma), pelleted, washed with XVIVO, and resuspended in XVIVO media with 1% human AB 
serum at the concentration of 106 cells/mL. Then the cells were stimulated with 1000U IL-2 
(Peprotech) for 10 minutes at 37°C, fixed with BD Fix/Lyse buffer (BD Bioscience) for 10 
minutes at 37°C, and then washed with cold PBS with 0.2% BSA. Next, the fixed cells were 
permeabilized with -20°C methanol for 20 minutes on ice, washed 5 times with cold PBS with 
0.2% BSA, and then stained with surface and intracellular flow cytometry antibodies for 30 
minutes at 4°C The fixed, permeabilized, and stained cells were washed with PBS and 
resuspended in PBS with 0.2% BSA for flow cytometry analysis. In Newcastle, thawed PMBCs 
were rested for 4 hours in serum-free RPMI-media. After the addition of surface markers and a 
fixable viability dye, 2x 105 cells were stimulated for 10 minutes at 37°C with 100 ng/mL of 
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either IL-2, IL-7, IL-15 or left unstimulated. The Transcription Factor Phospho Buffer set (BD 
Biosciences) was used to fix and permeabilize cells according to the manufacturer’s instructions. 
Cells were stained with the remaining surface as well as intracellular markers for 45 minutes at 
4°C before cells were washed in TFP Perm/Wash buffer and finally resuspended in FACS buffer 
for acquisition.  
 
Site-Directed Mutagenesis  
The wild-type pME18S-IL2RB template plasmid (~5000 bp) was obtained from the NIH. Site-
directed mutagenesis of T230C (p.L77P) was performed using the In-Fusion HD Cloning Kit 
(Takara Clontech) and following PCR primers (Sigma Aldrich):  
F: AGCTGCCCCCCGTGAGTCAA and R: TCACGGGGGGCAGCTCACAGGTTT.  
The linearized vector was generated by PCR using the CloneAmp HiFi PCR master mix (Takara 
ClonTech), plasmid template, and primers with the following thermocycling conditions: 35 
cycles of 10 seconds at 98°C, 5 seconds at 55°C, and 25s at 72°C. The PCR products were 
separated on a 1% agarose gel by gel electrophoresis and the desired mutagenized product band 
was cut out. The PCR product was purified using the NucleoSpin Gel and PCR Clean Up 
(Takara) from the InFusion Cloning Kit. The linearized, mutagenized product was ligated using 
the InFusion Enzyme (Takara) to generate the L77P mutant pME18S-IL2RB plasmid. Stellar 
cells (Takara) were transformed with the new plasmid by heat shock; the transformed cells were 
plated on ampicillin plates and incubated overnight at 37°C. Plasmid was extracted from 
individual colonies using the QIAprep Spin MiniPrep Kit (Qiagen). The mutation was confirmed 
by Sanger sequencing.  
 
Cloning  
Using wild-type and mutant pME18S-IL2RB plasmids as the template, wtIL2RB and mutIL2RB 
PCR products with AsiSI and SpeI restriction sites were generated using the following primers:  
F: tagtaggcgatcgcgccaccATGGCGGCCCCTGCTCTGTC and R: 
ctactaactagtCACCAAGTGAGTTGGGTCCTGAC. The PCR products were purified by gel 
electrophoresis. Next the gel purified PCR products and pHTC-P2A plasmid (provided by John 
James) were digested with AsiSI and SpeI restriction enzymes in CutSmart Buffer (NEB) for 2 
hours at 37°C and then purified by gel electrophoresis. IL2RB wt and mutant were ligated into 
separate custom-made pHTC/pBR322-P2A vectors using T4 DNA ligase (NEB). DH5alpha 
competent bacteria (NEB) were transformed with pHTC-wtIL2RB and pHTC-mutIL2RB and 
plated on Amp plates overnight. Individual colonies were Sanger sequenced to confirm 
successful cloning. pHTC-wtIL2RB, pHTC-mutIL2RB, and pGFP (provided by John James) 
were digested with mLuI and BamHI in NEB3.1 buffer and then purified by gel electrophoresis. 
Similar to above, GFP was ligated in to the pHTC vectors to generate pHTC-wtIL2RB-P2A-GFP 
and pHTC-mutIL2RB-P2A-GFP. The final plasmids were transformed in to DH5alpha bacteria, 
and individual colonies were Sanger sequenced again.  
 
HEK293T Transfection and Confocal Imaging 
HEK293T cells were cultured in complete DMEM or RPMI at 37°C in T75 flasks. 4x105 cells in 
2mL media were seeded into 6 well plates and grown overnight at 37°C At 40-50% confluence, 
the cells were transfected using 97uL OPTI-MEM (Gibco) and 3uL GeneJuice Transfection 
Reagent (VWR) per 1ug DNA. Cells were transfected with 1:pHTC-wtIL2RB-P2A-GFP and 
pHR-TetON-P2A-BFP, 2:pHTC-mutIL2RB-P2A-GFP and pHR-TetON-P2A-BFP, 3:pHTC-
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wtIL2RB-P2A-GFP, 4:pHTC-mutIL2RB-P2A-GFP, and 5:pHR-TetON-P2A-BFP. Six hours 
after transfection with pHTC-IL2RB-P2A-GFP and pHR-TetON-P2A-BFP, cells were dosed 
with doxycycline (1ug/ml). The transfected cells were cultured overnight at 37°C, pelleted, 
washed with PBS, and stained with CD122-PE-Dazzle antibody for flow cytometry analysis. 
Similarly, HEK293T cells were transfected with pHR-wtIL2RB-GFP or pHR-mutIL2RB-GFP 
and pBFP-KDEL in the same conditions in fibronectin-coated dishes for confocal imaging. An 
Andor spinning disc confocal microscope system was used to image the live cells at 37°C. Under 
the same conditions, HEK293T cells were also transfected with pME-IL2RG, pME-JAK3, pME-
STAT5-HA, pBFP, and different IL2RB plasmids to reconstitute the IL-2 receptor. After 
successful transfection, the cells were stimulated with high dose IL-2 and STAT phosphorylation 
was measured by flow cytometry as described above.  
 
IL-2 binding assay 
HEK293T cells were transfected with wild type and mutant IL-2RB and IL-2RG using the same 
transfection conditions as described above. 1x105 transfected cells in 0.2 mL 0.2% BSA-PBS 
were incubated with 200, 100, 10, 1, or 0.01 nM biotinylated IL-2 (R&D Systems) for 30 
minutes at 4oC. Then streptavidin-AlexaFluor 633 (1ug/mL, Invitrogen) was added and 
incubated for 15 minutes at 4 oC. Each sample was then washed 3x with 1mL PBS. The cells 
were resuspended in 300uL FACS buffer for subsequent FACS analysis. This protocol was 
adopted from Pillet et al. 2008.  
 
NK degranulation and cytotoxicity assays 
PBMCs were seeded at 1x105 per well in a 96-well plate and primed with either IL-2 or IL-15 
(100ng/ml each) for 12 hours or left unprimed. After the priming period, cells were co-incubated 
with K562 target cells (E:T ratio of 10:1) for 3 hours. Alongside with K562 exposure the 
CD107a-antibody was added to the wells.  Cells were harvested and surface staining  was carried 
out for 60 minutes on ice. Degranulation was measured by means of CD107a surface expression. 
Cytotoxicity was assessed by calculating the percentage of 7-AAD positive K562 after co-
incubation minus the spontaneous K562 death rate when cultured alone. The addition of IL-2 or 
IL-15 was found to not affect the viability of K562 cells. 
 
Interferon-γ production: 
PBMCs (1x105 in 100 ul) were stimulated with either IL-2, IL-15 or IL-12 (100 ng/ml each, all 
from Peprotech) for six hours with Brefeldin A (BD GolgiStop) added for the final five hours. 
Cells were fixed and permeabilized using Cytofix/Cytoperm buffers (BD) according to the 
manufacturer’s instructions and surface as well as intracellular staining were carried out for 30 
minutes at 4oC.  
 
Enzyme-linked immunosorbent assay (ELISA) 
Serum was analyzed for IL-2 using IL-2 ELISA kit (Invitrogen) and for IL-15 using IL-15 High 
Performance Luminex kit (R&D Systems).  
 
T cell proliferation 
2x105 PBMC were incubated in triplicates per experimental condition with the indicated stimuli 
for 3 days before being pulsed with tritiated thymidine for 8 hours.  A scintillation beta-counter 
was used to measure incorporation into dividing cells. 
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Molecular Modeling 
Starting models were derived from a crystal structure of IL-2RB in complex with IL2-IL-2RB 
and IL-2 determined at 2.3 Å resolution (PDB: 5M5E) (Klein et al., 2017). For the S40L variant, 
the Leu40 side chain was modelled with COOT (Emsley and Cowtan, 2004) without molecular 
dynamics (MD) simulation. For the L77P variant, the Pro77 side chain was placed in the 
experimental electron density of Leu77 with COOT while minimizing clashes with surrounding 
atoms to achieve a favourable initial geometry. The GROMACS software package (Abraham et 
al., 2015) was used to set up and run MD simulations. The AMBER99SB-ILDN force field 
(Lindorff-Larsen et al., 2010) and TIP3P water model were used and the structures placed in 
dodecahedral boxes with 10 Å padding and surrounded with solvent including water and 150 
mM NaCl. After steepest-gradient energy minimization, a modified Berendsen thermostat (2 
groups, time constant 0.1 picoseconds, temperature 310 K) followed by a Berendsen barostat 
(isotropic, coupling constant 0.5 picoseconds, reference pressure 1 bar) were coupled to the 
system over 100 picoseconds. One hundred-nanosecond runs of unrestrained MD trajectories 
were produced. After removal of periodic boundary condition artefacts, MD runs were visualized 
and analysed in UCSF Chimera (Pettersen et al., 2004) and bulk statistics extracted using 
GROMACS analysis routines. 
  
Lentiviral Transduction 
Wild-type IL2RB was cloned into a pHR-GFP transfer plasmid. Lenti-X 293T cells (Clontech) 
were transfected with the pHR-IL2RB-GFP transfer plasmid, pSPAX2, and pMD2.g plasmid in 
OPTIMEM and PEI. Lentivirus was harvested at 24, 48, and 72 hours post-transfection. The 
viral supernatants were pooled and concentrated using Lenti-X concentrator (Clontech). An 
aliquot of the concentrated lentivirus was quantified by qPCR using the Lenti-X qRT-PCR 
Titration Kit (Clontech). PBMCs were thawed and cultured in complete RPMI with IL-7. The 
cells were activated with CD3/CD28 Dynabeads (Gibco) for at least 24 hours prior to lentiviral 
transduction. After activation, PBMCs were transduced with a ratio of 100:1 WT-IL2RB 
lentivirus:PBMCs on retronectin-coated plated by spinfection. The cells were transduced for 72 
hours in complete RPMI with IL-7. Transduction efficiency was measured by FACS and 
transduced cells were subsequently assessed for STAT phosphorylation after IL-2 stimulation.  
 
Online Supplemental Material 
Figure S1 shows healthy control and patient T cell proliferative responses to PHA, anti-
CD3, anti-CD3 and IL-2, and PMA and ionomycin. Figure S2 shows the molecular 
dynamic simulation results for wild-type, S40L, and L77P IL-2Rb. Figure S3 shows the 
FACS plots for CD25 upregulation, CD107a degranulation and interferon-γ expression in 
healthy control and patient NK cells.  
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Figure Legends 
 
Figure 1. Genetic and clinical features of the disease cohort.   
A. Four consanguineous pedigrees of eight affected individuals (A1-D3) with three different 
homozygous recessive mutations. B. Radiographic evidence for pulmonary disease in Kindred A. 
Panels 1 and 2 show a left pleural effusion. Hepatosplenomegaly can also be seen in Panel 1. 
Panels 3 and 4 show numerous small pulmonary nodules and tree-in-bud changes suggestive of 
pneumonia. Red arrows highlight 2 small lung nodules. Panel 5 shows enlarged axillary lymph 
nodes (red arrows). C. Immunohistochemistry of fetal skin from kindred D, patients D1, D2, and 
D3 stained in brown for the lymphocyte markers as indicated. Black scale bar = 50um.  
D. Immunohistochemistry of duodenal (left) and rectal (right) biopsies of patient B1 and healthy 
control, stained with indicated markers. Purple: CD20, CD4, and FoxP3; Yellow: CD3, CD8, 
and CD4 for the respective panels. Black scale bar = 100um. E. Summary of clinical hallmarks 
of IL-2R  deficiency in the five pediatric patients. Skin abnormalities were observed in the 
individuals in kindred D in addition to the pediatric patients (8 total).  
 
Figure 2. IL-2Rb coding mutations cause IL-2Rb surface receptor deficiency.  
A. Schematic of intracellular (ICD) and extracellular domains (ECD) of the IL-2Rb protein 
depicting the location of the three mutations in the ECD. The signal peptide is highlighted in 
orange and the canonical WSXWS motif is highlighted in green. B. Crystal structure of IL-2:IL-
2R complex with the expanded view showing the position of the three mutations in white: L77P, 
S40L, and Q96*; (modified from PDB 2B5I, Wang et al. 2005). Red: IL-2/15Rb, blue: IL-2Rg, 
green: IL-2Ra, and yellow: IL-2 with IL-2Rb interface colored in red. C. Histogram of IL-2Rb 
surface expression in CD3+ CD4+ (red) ,CD3+ CD8+ (blue), and CD3- CD56+ NK cells (green) 
from patient B1 compared to healthy control (top 3 panels: healthy control, bottom 3 panels). D. 
Histogram of IL-2Rb surface expression in NK cells (CD3- CD56+) (red = homozygous affected 
A1, blue = heterozygote healthy A0, black=healthy control). Data representative of 4 
independent experiments. E. Western blot of FACS-sorted CD3- CD56+ NK cells from A1, 
heterozygote parent (A0), B1, and four healthy controls (HC1-4). F. Western blot of FACS-
sorted CD3+ CD8+ T cells from A1, heterozygote parent (A0), and three healthy controls (HC1-
3). G. Western blot of FACS-sorted CD3+ CD4+ T cells from A1, heterozygote parent (A0), B1, 
and three healthy controls (HC1-3). H. Western blot of fetal thymuses from Kindred D (D1-D3) 
and five fetal thymic controls from 25 weeks old (FT3-FT4) and 31 weeks old (FT1, FT2, FT5). 
E-H, loading control: Actin. Western blots (2E-2H) were repeated in triplicate. 
 
Figure 3. Investigation of IL-2Rb deficiency mechanisms in a HEK293T transfection 
model. 
A. FACS plot of GFP and IL-2Rb expression by HEK293T cells transfected with pHTC-
wtIL2RB (red) and pHR-TetON-BFP or transfected with pHTC-mutIL2RB (blue) and pHR-
TetON-BFP. B. Histograms of BFP, GFP, or IL-2RB expression given the listed four 
transfection conditions: wild-type, mutant, TetON only, and no transfection. C. Western blot of 
HEK293T cells transfected with pHTC-wtIL2RB-GFP or pHTC-mutIL2RB-GFP. Loading 
controls: actin and GFP. D. Confocal images of live HEK293T cells co-transfected with KDEL-
BFP (ER localization marker) and WT-IL2RB-GFP or Mut-IL2RB-GFP. White scale bar = 
10um. E. Graph of normalized surface IL-2RB expression in HEK293T cells with exogenous IL-
2 receptor system for the three disease-causing IL-2RB mutations. *p<0.05, Mann-Whitney U 
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test. F. Graph of pSTAT5 response to high dose IL-2 in HEK293T cells with exogenous IL-2 
receptor system. *p<0.05, Mann-Whitney U test. G. Molecular dynamic simulation of the 
receptor cytokine binding interface in WT IL-2Rb and the S40L variant. The IL-2R subunit is 
coloured in blue, IL-2Rb in red and IL-2 in yellow (PDB: 5M5E). The structure of S40L mutant 
after 100 ns of molecular dynamics (MD) simulation (green) is shown superimposed on the 
structure of the WT IL-2Rb after 100 ns MD simulation (red). The leucine side chain clashes 
with main chain atoms in the BC2 loop (residues 157-165) of the D2 domain, which contributes 
directly to IL-2 binding. A zoomed in panel of the IL-2 and MD simulated S40L mutant IL-2Rb 
interface is provided. H. Graph of IL-2 binding by WT IL-2Rb, S40L mutant, and no IL-2Rb 
negative control in HEK293T cells measured by flow cytometry using a biotin-streptavidin 
system. Experiments (3A-3F and 3H) were repeated in triplicate with graphs showing mean ± 
SEM.  
 
Figure 4. IL-2Rb deficiency abrogates IL-2 induced STAT3 and STAT5 phosphorylation in 
peripheral T cells. 
Flow cytometry-based measure of STAT3 phosphorylation in CD3+ CD4+ T cells from healthy 
controls (HC), heterozygote parent A0 (WT/Mut), and homozygous affected A1 (Mut/Mut). B. 
STAT5 phosphorylation in CD3+ CD4+ T cells. C. STAT3 phosphorylation in CD8 T cells. D. 
STAT5 phosphorylation in CD8+ T cells. (red=representative healthy control, 
blue=representative affected, lighter shade=unstimulated, darker shade=stimulated with 1000U 
IL-2). E. STAT5 phosphorylation in CD4+ and CD8+ T cells (B1) in response to IL-2, IL-7, and 
IL-15 stimulation. F. Flow cytometry plot of CD25 and FoxP3 expression in healthy control and 
homozygous affected (B1). Data representative of 3 independent experiments. G. Graphs of IL-2 
and IL-15 levels in healthy controls, A0 (healthy heterozygous father of A1), patient A1, and 
patient B1 serum. H. Graphs of percent of CD25high cells in healthy control (blue), patient B1 
(red square), and patient A1 (red triangle) CD4+ T cells, CD8+ T cells, and NK cells that have 
been primed with IL-2 or IL-15 for 12 hours or left unprimed. ****p < 0.0001, ***p < 0.001, 
**p < 0.01, *p < 0.05, Mann-Whitney U tests were performed in A-D, and G. Student t-test was 
performed in H. Experiments (4A-4H) were performed in triplicate with graphs showing mean ± 
SD.  
 
Figure 5. NK cells retain IL-2/IL-15 responsiveness and effector function but is deficient in 
adaptive “memory-like” NK subsets.  
A. Flow cytometry plot of CD16 and CD56 expression in CD3- CD19- lymphocytes (patient B1), 
representative of 4 independent experiments B. Histograms of Granzyme B and Perforin content 
in CD56bright versus CD56dim NK cells. Healthy control in blue, patient B1 in red. Experiment 
displayed representative of 3 independent experiments. C. STAT5 phosphorylation in NK cells 
(B1) in response to IL-2, IL-7, and IL-15 stimulation. D. CD107a expression (degranulation) in 
healthy control and patient B1 NK cells co-cultured with K562 cells after 12 hours of priming 
with IL-2 or IL-15 or left unprimed.  E. Percentage of 7-AAD-positive, i.e. dead, K562 cells as a 
measure of cytotoxicity when co-cultured with healthy control (blue circles) NK cells or patient 
B1 (red squares) NK cells. F. Interferon-γ production in response to the indicated stimuli in 
control NK cells (blue circles) or patient B1 NK cells (red squares). G. Expression of NKG2C 
and CD57 on NK cells of CMV+ control and patient B1. H. Summary graph displaying the 
percentage of CD57+ positivity within the NKG2C+ and NKG2C- NK cell subsets (mean ± SD). 
Data representative of 6 independent experiments. I. FACS plots of FcεRIg, PLZF and Syk 
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expression in CMV- and CMV+ healthy controls and well as  patient B1, gated on NKG2C-
expressing NK cells. J. Summary graphs showing the percentage of NKG2C+ NK cells 
downregulating the indicated proteins. ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05, 
student t-tests were performed. Experiments 5D-5F were performed in duplicate and 5A-5C, 5G-
5J were performed in triplicate with graphs showing mean ± SD.  
 
Figure 6. Lentiviral rescue of IL-2Rb and STAT phosphorylation in primary T cells.  
A. Histogram showing GFP expression in patient A1 CD3+ T cells transduced (red) with 
lentiviral wild-type IL-2Rb and GFP and no transduction control (blue). B. Histogram showing 
IL-2Rb expression in patient A1 CD3+ T cells transduced (red) with lentiviral wild-type IL-2RB 
and GFP and no transduction control (blue). C. Histograms showing STAT3 phosphorylation in 
response to IL-2 stimulation in transduced (dark red) and non-transduced (dark blue) CD3+ A1 T 
cells. D. Histograms showing STAT5 phosphorylation in response to IL-2 stimulation in 
transduced (dark red) and non-transduced (dark blue) CD3+ A1 T cells. E. Graph of delta MFI of 
pSTAT5 between IL-2 stimulated and unstimulated in healthy controls and L77P patients A1 and 
B1 transduced and no transduction control. *p<0.05, Mann-Whitney U test, n.s.= not significant. 
Experiments 6A-6E were performed in triplicate with the graph showing mean ± SEM.  
 
Supplementary Figure S1. T cell proliferative responses. Graph of T cell proliferative 
responses to PHA, anti-CD3, anti-CD3 and IL-2, and PMA/ionomycin in patient B1 and healthy 
control cells based on thymidine incorporation. 
 
Supplementary Figure S2. Molecular dynamic simulation of WT, S40L, and L77P IL-2Rb 
structures. A. Root mean square deviation (RMSD) between the WT, S40L, and L77P IL-2Rb 
structures over 100 nanoseconds of unrestrained MD simulation with explicit solvent. B. Root 
mean square fluctuation (RMSF) in WT, S40L, and L77P IL-2Rb over the complete trajectory. 
 
Supplementary Figure S3. A. FACS plots demonstrating upregulation of CD25 in CD3-CD56+ 
NK cells from a healthy control (top panel) or patient B1 (bottom panel) either unprimed or after 
priming with IL-2 or IL-15 (100 ng/ml each) for 12 hours followed by a 3 hour co-incubation 
period with K562 cells. B. FACS plots showing surface expression of CD107a in CD3-CD56+ 
NK cells from a healthy control (top panel) or patient B1 (bottom panel) either unprimed or after 
priming with IL-2 or IL-15 (100 ng/ml each) for 12 hours in response to co-incubation period 
K562 cells for 3 hours. C. Intracellular staining for Interferon-γ in CD3-CD56+ NK cells from a 
healthy control (top panel) or patient B1 (bottom panel) after stimulation with IL-2, IL-15 or IL-
12 (100 ng/ml each) for 6 hours. 
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Table 1. Patient mutations and clinical manifestations 
 
 
 
Table 2. Lab values and absolute cell counts  
 
 
 
 
 
 
 35 
Table 3. Rare variants that were identified and co-segregated in the kindred 
 
 
 
 
 
